Rhumbline Advisers Krystal Biotech, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 70,309 shares of KRYS stock, worth $10.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

70,309

Previous 71,685 1.92%

Holding current value

$10.9 Million

Previous $13.2 Million 2.88%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$174.7 - $213.66 $240,387 - $293,996	-1,376 Reduced 1.92%	70,309 $12.8 Million
Q2 2024 Aug 01, 2024	BUY	$153.12 - $183.64 $6.06 Million - $7.27 Million	39,586 Added 123.32%	71,685 $13.2 Million
Q1 2024 May 09, 2024	BUY	$108.01 - $179.35 $33,915 - $56,315	314 Added 0.99%	32,099 $5.71 Million
Q4 2023 Feb 08, 2024	SELL	$96.0 - $128.29 $59,328 - $79,283	-618 Reduced 1.91%	31,785 $3.94 Million
Q3 2023 Nov 09, 2023	BUY	$108.51 - $130.22 $150,611 - $180,745	1,388 Added 4.48%	32,403 $3.76 Million
Q2 2023 Aug 08, 2023	SELL	$78.48 - $130.32 $114,109 - $189,485	-1,454 Reduced 4.48%	31,015 $3.64 Million
Q1 2023 May 11, 2023	BUY	$72.39 - $84.27 $45,967 - $53,511	635 Added 1.99%	32,469 $2.6 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $44,892 - $56,808	711 Added 2.28%	31,834 $2.52 Million
Q3 2022 Nov 10, 2022	BUY	$64.85 - $82.4 $171,074 - $217,371	2,638 Added 9.26%	31,123 $2.17 Million
Q2 2022 Aug 11, 2022	BUY	$48.93 - $73.47 $227,328 - $341,341	4,646 Added 19.49%	28,485 $1.87 Million
Q1 2022 May 12, 2022	BUY	$51.99 - $72.11 $112,922 - $156,622	2,172 Added 10.02%	23,839 $1.59 Million
Q4 2021 Feb 10, 2022	BUY	$39.81 - $88.24 $4,896 - $10,853	123 Added 0.57%	21,667 $1.52 Million
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $44,728 - $61,722	860 Added 4.16%	21,544 $1.13 Million
Q2 2021 Aug 05, 2021	BUY	$62.14 - $81.82 $353,265 - $465,146	5,685 Added 37.9%	20,684 $1.41 Million
Q1 2021 May 06, 2021	SELL	$59.42 - $85.46 $6,595 - $9,486	-111 Reduced 0.73%	14,999 $1.16 Million
Q4 2020 Feb 10, 2021	BUY	$40.64 - $61.38 $58,318 - $88,080	1,435 Added 10.49%	15,110 $907,000
Q3 2020 Nov 12, 2020	SELL	$37.76 - $48.49 $57,395 - $73,704	-1,520 Reduced 10.0%	13,675 $589,000
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $111,830 - $181,200	3,020 Added 24.8%	15,195 $629,000
Q1 2020 May 06, 2020	BUY	$35.02 - $65.64 $30,362 - $56,909	867 Added 7.67%	12,175 $526,000
Q4 2019 Feb 05, 2020	BUY	$33.17 - $65.23 $34,430 - $67,708	1,038 Added 10.11%	11,308 $626,000
Q3 2019 Oct 23, 2019	BUY	$34.72 - $51.3 $56,038 - $82,798	1,614 Added 18.65%	10,270 $357,000
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $235,443 - $356,627	8,656 New	8,656 $349,000

Others Institutions Holding KRYS

# of Institutions

306

Shares Held

24.2M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Krystal Biotech, Inc. Transaction History